Lower-dose epcoritamab with gemcitabine and oxaliplatin for relapsed diffuse large B-cell lymphoma
Tests lower-dose epcoritamab with chemotherapy in adults whose lymphoma returned.
Plain-language title generated from the registry record
Registry title: Low Dose Epcoritamab Plus GemOx in R/R DLBCL
Key facts
- Where
- Monterrey, MexicoSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07451652, who can take part
Where in Mexico
- Hospital Universitario Dr. Jose Eleuterio GonzálezMonterrey, MexicoTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hospital Universitario Dr. Jose E. Gonzalez
- Trial code
- NCT07451652
- Record updated
- 1 April 2026
- Original description
In this study, researchers are looking to determine whether Gemcitabine/Oxaliplatin plus a lower dose of Epcoritamab (12 mg) works to treat subjects with relapsed/refractory diffuse large B-cell lymphoma, who are candidates to autologous stem cell transplantation.Read full original descriptionShow less
Low Dose Epcoritamab Plus Gemcitabine/Oxaliplatin in Treatment of Transplant Eligible Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
In this study, researchers are looking to determine whether Gemcitabine/Oxaliplatin plus a lower dose of Epcoritamab (12 mg) works to treat subjects with relapsed/refractory diffuse large B-cell lymphoma, who are candidates to autologous stem cell transplantation.
Inclusion: Subjects with relapsed/refractory diffuse large B-cell lymphoma who have received at least 1 previous line of treatment and that are candidates to autologous stem cell transplant; ECOG 0-2; Women of reproductive age who agree on getting a contraceptive method; Subjects who fulfill Lugano´s criteria for disease activity; Subjects who voluntarily accept to participate in this study.
Exclusion: Subjects who have already received an autologous o allogeneic stem cell transplantation; Active bacterial, viral or fungal infection; Subjects with end-stage failure; Subjects with other active neoplasias.